599 results on '"Jazaeri, Amir A."'
Search Results
2. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer
3. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis
4. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
5. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab
6. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.
7. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.
8. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.
9. Clinical and genomic landscape of RAS mutations in gynecologic cancers
10. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs
11. Immuno-Oncology for Gynecologic Malignancies
12. Abstract A077: The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer
13. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
14. Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer
15. Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer
16. Immuno-oncology for Gynecologic Malignancies
17. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer
18. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer
19. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction
20. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
21. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
22. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
23. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
24. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
25. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma
26. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer
27. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
28. 1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
29. Transforming ovarian cancer care by targeting minimal residual disease
30. SO013/#983 Intraoperative identification of ovarian cancer during tumor reductive surgery using the hand-held masspec pen technology
31. EP159/#1534 Leveraging personalized circulating tumor DNA monitoring to predict treatment response and recurrence in high-risk endometrial cancer
32. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
33. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls
34. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
35. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation
36. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
37. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice
38. Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
39. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature
40. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer
41. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
42. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
43. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
44. Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube
45. Supplemental Tables from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
46. Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
47. Abstract 5473: Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancer
48. Supplemental Table Legends from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
49. Supplementary Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
50. Table S3 from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.